File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: The significance of unrecognized histological high-risk features on response to therapy in papillary thyroid carcinoma measuring 1-4cm: implications for completion thyroidectomy following lobectomy

TitleThe significance of unrecognized histological high-risk features on response to therapy in papillary thyroid carcinoma measuring 1-4cm: implications for completion thyroidectomy following lobectomy
Authors
KeywordsATA risk stratification
TNM staging
disease recurrence
disease-free survival
distant metastasis
lymphovascular invasion
papillary thyroid carcinoma
Issue Date2016
PublisherWiley-Blackwell Publishing Ltd. The Journal's web site is located at http://www.wiley.com/bw/journal.asp?ref=0300-0664
Citation
Clinical Endocrinology, 2016 How to Cite?
AbstractBACKGROUND: Although lobectomy is an alternative to total thyroidectomy (TT) for 1-4cm papillary thyroid carcinoma (PTC) without high-risk features (HRFs) like aggressive histology, vascular invasion, lymphovascular invasion (LVI), microscopic extrathyroidal extension, positive margin, nodal metastasis >5mm and multifocality, these HRFs are not recognized until after surgery. Therefore, the chance of completion TT being required following lobectomy might be high. We evaluated the frequency of unrecognized HRFs and how they affected the response to therapy following TT and radioiodine (RAI). METHODS: Altogether 1513 patients were analyzed. Only 1-4cm PTCs without recognizable HRFs were included. For response-to-therapy evaluation, only patients who had TT and post-RAI stimulated thyroglobulin were analyzed. Patients without an excellent response were defined as having 'incomplete response'. A multivariate analysis for incomplete response was done. RESULTS: Of the 600 patients eligible for lobectomy, 257 (42.8%) had ≥1 unrecognized histological HRF before surgery. The prevalence of unrecognized HRFs was similar between 1-2cm and >2-4cm PTCs (p=0.393). Of the 330 patients eligible for response-to-therapy evaluation, 260 (78.8%) had an excellent response while 70 (21.2%) had an incomplete response. LVI was the only independent unrecognized HRF for incomplete response (p=0.021). CONCLUSIONS: The prevalence of unrecognized histological HRFs under the current recommendations is relatively high among 1-4cm PTCs. Among the unrecognized histological HRFs, LVI was the only one which independently associated with an incomplete response (i.e. posing an increased risk of persistent/recurrent disease after curative surgery). These findings may have implications for patients who undergo lobectomy for 1-4cm PTCs with no clinically recognizable HRFs under the current recommendations. This article is protected by copyright. All rights reserved.
Persistent Identifierhttp://hdl.handle.net/10722/229505
ISSN
2021 Impact Factor: 3.523
2020 SCImago Journal Rankings: 1.055
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorLang, HHB-
dc.contributor.authorShek, TWH-
dc.contributor.authorWan, KY-
dc.date.accessioned2016-08-23T14:11:34Z-
dc.date.available2016-08-23T14:11:34Z-
dc.date.issued2016-
dc.identifier.citationClinical Endocrinology, 2016-
dc.identifier.issn0300-0664-
dc.identifier.urihttp://hdl.handle.net/10722/229505-
dc.description.abstractBACKGROUND: Although lobectomy is an alternative to total thyroidectomy (TT) for 1-4cm papillary thyroid carcinoma (PTC) without high-risk features (HRFs) like aggressive histology, vascular invasion, lymphovascular invasion (LVI), microscopic extrathyroidal extension, positive margin, nodal metastasis >5mm and multifocality, these HRFs are not recognized until after surgery. Therefore, the chance of completion TT being required following lobectomy might be high. We evaluated the frequency of unrecognized HRFs and how they affected the response to therapy following TT and radioiodine (RAI). METHODS: Altogether 1513 patients were analyzed. Only 1-4cm PTCs without recognizable HRFs were included. For response-to-therapy evaluation, only patients who had TT and post-RAI stimulated thyroglobulin were analyzed. Patients without an excellent response were defined as having 'incomplete response'. A multivariate analysis for incomplete response was done. RESULTS: Of the 600 patients eligible for lobectomy, 257 (42.8%) had ≥1 unrecognized histological HRF before surgery. The prevalence of unrecognized HRFs was similar between 1-2cm and >2-4cm PTCs (p=0.393). Of the 330 patients eligible for response-to-therapy evaluation, 260 (78.8%) had an excellent response while 70 (21.2%) had an incomplete response. LVI was the only independent unrecognized HRF for incomplete response (p=0.021). CONCLUSIONS: The prevalence of unrecognized histological HRFs under the current recommendations is relatively high among 1-4cm PTCs. Among the unrecognized histological HRFs, LVI was the only one which independently associated with an incomplete response (i.e. posing an increased risk of persistent/recurrent disease after curative surgery). These findings may have implications for patients who undergo lobectomy for 1-4cm PTCs with no clinically recognizable HRFs under the current recommendations. This article is protected by copyright. All rights reserved.-
dc.languageeng-
dc.publisherWiley-Blackwell Publishing Ltd. The Journal's web site is located at http://www.wiley.com/bw/journal.asp?ref=0300-0664-
dc.relation.ispartofClinical Endocrinology-
dc.rightsPreprint This is the pre-peer reviewed version of the following article: [FULL CITE], which has been published in final form at [Link to final article]. Authors are not required to remove preprints posted prior to acceptance of the submitted version. Postprint This is the accepted version of the following article: [full citation], which has been published in final form at [Link to final article].-
dc.subjectATA risk stratification-
dc.subjectTNM staging-
dc.subjectdisease recurrence-
dc.subjectdisease-free survival-
dc.subjectdistant metastasis-
dc.subjectlymphovascular invasion-
dc.subjectpapillary thyroid carcinoma-
dc.titleThe significance of unrecognized histological high-risk features on response to therapy in papillary thyroid carcinoma measuring 1-4cm: implications for completion thyroidectomy following lobectomy-
dc.typeArticle-
dc.identifier.emailLang, HHB: blang@hkucc.hku.hk-
dc.identifier.emailShek, TWH: whshek@hkucc.hku.hk-
dc.identifier.authorityLang, HHB=rp01828-
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1111/cen.13165-
dc.identifier.pmid27467318-
dc.identifier.scopuseid_2-s2.0-84992222150-
dc.identifier.hkuros261656-
dc.identifier.isiWOS:000393452300012-
dc.publisher.placeUnited Kingdom-
dc.identifier.issnl0300-0664-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats